SCHEMBL14983465

SCHEMBL14983465

COc1ccc(-c2nc3ncnc(O)c3nc2-c2ccc(OC)c(OC)c2)cc1OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CG P48736 6/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ ADK P55263 2/20 0.44
▸ GAK O14976 1/20 0.44
▸ POLB P06746 1/20 0.43
▸ PIK3CD O00329 3/20 0.40
▸ PIK3CA P42336 3/20 0.40
▸ PIK3CB P42338 3/20 0.40
▸ MTOR P42345 3/20 0.40
▸ ALDH1A1 P00352 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ GAA P10253 1/20 0.40
▸ MPI P34949 1/20 0.40
▸ GFER P55789 1/20 0.40
▸ APOBEC3G Q9HC16 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ PDGFRB P09619 1/20 0.40
▸ PDGFRA P16234 1/20 0.40
▸ ABL1 P00519 2/20 0.39
▸ EGFR P00533 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14983470 0.90 POLB (0.56) PIK3CGPOLBPIK3CDPIK3CAPIK3CB
SCHEMBL14983475 0.81 PIK3CG (0.50) PIK3CGL3MBTL1ADKALDH1A1KDM4E
SCHEMBL17089216 0.80 PIK3CG (0.55) PIK3CGPIK3CDPIK3CAPIK3CBMTOR
SCHEMBL12068931 0.80 PIK3CG (0.50) PIK3CGL3MBTL1GAKPOLBPIK3CD
SCHEMBL14983476 0.76 PIK3CG (0.71) PIK3CGADKPOLBALDH1A1KDM4E
SCHEMBL4361291 0.72 PIK3CG (0.53) PIK3CGL3MBTL1ADKPOLBMTOR
SCHEMBL14983452 0.70 PIK3CG (0.56) PIK3CGGAKPOLBPIK3CDPIK3CA
SCHEMBL3335439 0.70 BRAF (0.54) PIK3CGPIK3CDPIK3CAPIK3CBMTOR
SCHEMBL29619922 0.67 PIK3CG (0.37) PIK3CG
SCHEMBL14983458 0.67 ADORA1 (0.55) L3MBTL1POLBKDM4EPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160083388-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF TRT PHARMA INC. (CA) 2016-03-24 — — US disclosed
US-20160083388-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF TRT PHARMA INC. (CA) 2016-03-24 — — US disclosed
US-9139592-B2 Modulators of Nrf2 and uses thereof TRT PHARMA INC. (CA) 2015-09-22 — — US disclosed
US-9139592-B2 Modulators of Nrf2 and uses thereof TRT PHARMA INC. (CA) 2015-09-22 — — US disclosed
US-20130137694-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF TRT PHARMA INC. (CA) 2013-05-30 — — US disclosed
US-20130137694-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF TRT PHARMA INC. (CA) 2013-05-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137694-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF KEAP1, TXNRD1, NFE2L2 PIK3CG 3893/4885L3MBTL1 1364/4885ADK 3011/4885
US-20160083388-A1 NOVEL MODULATORS OF NRF2 AND USES THEREOF KEAP1, TXNRD1, NFE2L2 PIK3CG 3893/4885L3MBTL1 1364/4885ADK 3011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback